These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25034873)

  • 21. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
    Lawitz E; Sulkowski MS; Ghalib R; Rodriguez-Torres M; Younossi ZM; Corregidor A; DeJesus E; Pearlman B; Rabinovitz M; Gitlin N; Lim JK; Pockros PJ; Scott JD; Fevery B; Lambrecht T; Ouwerkerk-Mahadevan S; Callewaert K; Symonds WT; Picchio G; Lindsay KL; Beumont M; Jacobson IM
    Lancet; 2014 Nov; 384(9956):1756-65. PubMed ID: 25078309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
    Nelson DR; Cooper JN; Lalezari JP; Lawitz E; Pockros PJ; Gitlin N; Freilich BF; Younes ZH; Harlan W; Ghalib R; Oguchi G; Thuluvath PJ; Ortiz-Lasanta G; Rabinovitz M; Bernstein D; Bennett M; Hawkins T; Ravendhran N; Sheikh AM; Varunok P; Kowdley KV; Hennicken D; McPhee F; Rana K; Hughes EA;
    Hepatology; 2015 Apr; 61(4):1127-35. PubMed ID: 25614962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis.
    Ferreira VL; Assis Jarek NA; Tonin FS; Borba HH; Wiens A; Muzzillo DA; Pontarolo R
    J Gastroenterol Hepatol; 2017 Apr; 32(4):749-755. PubMed ID: 27785825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
    Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W
    Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis.
    Ogawa E; Furusyo N; Nomura H; Takahashi K; Higashi N; Kawano A; Dohmen K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
    Antiviral Res; 2016 Dec; 136():37-44. PubMed ID: 27789224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.
    Crespo J; Calleja JL; Fernández I; Sacristan B; Ruiz-Antorán B; Ampuero J; Hernández-Conde M; García-Samaniego J; Gea F; Buti M; Cabezas J; Lens S; Morillas RM; Salcines JR; Pascasio JM; Turnes J; Sáez-Royuela F; Arenas J; Rincón D; Prieto M; Jorquera F; Sanchez Ruano JJ; Navascués CA; Molina E; Moya AG; Moreno-Planas JM;
    Clin Gastroenterol Hepatol; 2017 Jun; 15(6):945-949.e1. PubMed ID: 28238958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience.
    Elfeki MA; Abou Mrad R; Modaresi Esfeh J; Zein NN; Eghtesad B; Zervos X; Hanouneh IA; O'Shea R; Carey WD; Alkhouri N
    Transplantation; 2017 May; 101(5):996-1000. PubMed ID: 27631598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
    Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
    World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
    Welzel TM; Nelson DR; Morelli G; Di Bisceglie A; Reddy RK; Kuo A; Lim JK; Darling J; Pockros P; Galati JS; Frazier LM; Alqahtani S; Sulkowski MS; Vainorius M; Akushevich L; Fried MW; Zeuzem S;
    Gut; 2017 Oct; 66(10):1844-1852. PubMed ID: 27418632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis.
    He QF; Zhang QF; Zhang DZ
    Dig Dis Sci; 2016 Nov; 61(11):3108-3117. PubMed ID: 27619394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
    Jacobson IM; Gordon SC; Kowdley KV; Yoshida EM; Rodriguez-Torres M; Sulkowski MS; Shiffman ML; Lawitz E; Everson G; Bennett M; Schiff E; Al-Assi MT; Subramanian GM; An D; Lin M; McNally J; Brainard D; Symonds WT; McHutchison JG; Patel K; Feld J; Pianko S; Nelson DR; ;
    N Engl J Med; 2013 May; 368(20):1867-77. PubMed ID: 23607593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ledipasvir + Sofosbuvir for Liver Transplant Recipients With Recurrent Hepatitis C: A Systematic Review and Meta-analysis.
    Liao HT; Tan P; Huang JW; Yuan KF
    Transplant Proc; 2017 Oct; 49(8):1855-1863. PubMed ID: 28923637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
    Afdhal N; Zeuzem S; Kwo P; Chojkier M; Gitlin N; Puoti M; Romero-Gomez M; Zarski JP; Agarwal K; Buggisch P; Foster GR; Bräu N; Buti M; Jacobson IM; Subramanian GM; Ding X; Mo H; Yang JC; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Mangia A; Marcellin P;
    N Engl J Med; 2014 May; 370(20):1889-98. PubMed ID: 24725239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience.
    El-Khayat HR; Kamal EM; El-Sayed MH; El-Shabrawi M; Ayoub H; RizK A; Maher M; El Sheemy RY; Fouad YM; Attia D
    Aliment Pharmacol Ther; 2018 Mar; 47(6):838-844. PubMed ID: 29349793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
    Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis.
    El Raziky M; Gamil M; Ashour MK; Sameea EA; Doss W; Hamada Y; Van Dooren G; DeMasi R; Keim S; Lonjon-Domanec I; Hammad R; Hashim MS; Hassany M; Waked I
    J Viral Hepat; 2017 Feb; 24(2):102-110. PubMed ID: 27790789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
    Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
    Liver Int; 2016 Sep; 36(9):1275-83. PubMed ID: 26928927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis.
    Dolatimehr F; Karimi-Sari H; Rezaee-Zavareh MS; Alavian SM; Behnava B; Gholami-Fesharaki M; Sharafi H
    Daru; 2017 Apr; 25(1):11. PubMed ID: 28427463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.